Serum quinidine concentrations and effect on QT dispersion and interval

Annals of Pharmacotherapy

Volumn 36, Issue 7-8, 2002, Pages 1156-1161

  Mathis, A Scott ^a   Gandhi, Ashesh J ^a   Lugo, Sonia I ^a   Rochefort, Esthel ^a  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

Author keywords

Quinidine; Torsade de pointes

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; HEPARIN; HYDRALAZINE; LOW MOLECULAR WEIGHT HEPARIN; QUINIDINE; WARFARIN;

ADULT; AGED; ARTICLE; CALCULATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG BLOOD LEVEL; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM ARRHYTHMIA; HUMAN; LONG QT SYNDROME; MALE; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; QT INTERVAL; RISK ASSESSMENT; TORSADE DES POINTES; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG INTERACTION; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ARRHYTHMIA; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINIDINE; RETROSPECTIVE STUDIES; TORSADES DE POINTES;

EID: 0036020180     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A472     Document Type: Article

References (31)

1. Evaluation of drug-induced QT interval prolongation. Implications for drug approval and labeling
2. Quinidine syncope: Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias
3. Quinidine-induced syncope
4. Quinidine syncope: A report of successful treatment with bretylium tosylate
5. Quinidine syncope: Torsade de pointes with low quinidine plasma concentrations
6. Torsade de pointes due to quinidine: Observations in 31 patients
7. Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care
8. Clinical features and basic mechanisms of quinidine-induced arrhythmias
9. Quinidine
10. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers: Relationship to potassium and cycle length
11. Kr: Implications for torsade de pointes and reverse use-dependence
12. Quinidine-induced long QTU interval and torsade de pointes: Role of bradycardia-dependent early afterdepolarizations
13. Taking the "idio" out of "idiosyncratic": Predicting torsade de pointes
14. QT dispersion: An indication of arrhythmia risk in patients with long QT intervals
15. Amiodarone-associated proarrhythmic effects: A review with special reference to torsade de pointes tachycardia
16. Precordial QT interval dispersion as a marker of torsade de pointes: Disparate effects of class Ia antiarrhythmics and amiodarone
17. Effects of amiodarone, semi-tilide, and sotalol on QT dispersion
18. QT-interval prolonging drugs: Mechanisms and clinical relevance of their arrhythmogenic hazards
19. The measurement of the QT interval of the electrocardiogram
20. An analysis of the time-relations of electrocardiograms
21. Measurement and interpretation of QT dispersion
22. Rate-dependence of QT dispersion and the QT interval: Comparison of atrial pacing and exercise testing
23. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine
24. Electrocardiographic and clinical predictors of torsade de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: A prospective study
25. "Late" proarrhythmia due to quinidine
26. Effects of aging and gender on QT dispersion in an overtly healthy population
27. Computer-assisted study of ECG indices of the dispersion of ventricular repolarization
28. Molecular basis of the long-QT syndrome associated with deafness
29. Measurement, interpretation and clinical potential of QT dispersion
30. Altered protein binding of quinidine in patients with atrial fibrillation and flutter
31. Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes